Emami Q1 Review - Margin Outlook Getting Better; Sales Recovery Key To Re-Rating: Motilal Oswal

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Motilal Oswal Report.Emami Ltd.’s Q1 FY22 sales were in line with expectations. Domestic sales grew 5% versus Q1 FY20 levels. While healthcare and pain management have nearly doubled over Q1 FY20 levels, the impact of the second Covid-19 wave led lockdown resulted in sharp decline over Q1 FY20 in Navratna (in the crucial summer season) and male grooming. The outlook for the domestic business gradually improved in June and July 2021, after modest growth over a two-year period in Q1 FY22. This was partly offset by slower growth in the international business (~12% of sales) due to Covid-19 related lockdowns, especially in the Middle East.Emami's margin performance in Q1 FY22 and the outlook were better than expected..Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Emami Q1 Review - Margin Outlook Getting Better; Sales Recovery Key To Re-Rating: Motilal Oswal

Emami Q1 Review - Margin Outlook Getting Better; Sales Recovery Key To Re-Rating: Motilal Oswal

Choose a plan